Exane BNP Paribas Upgrades Revance Therapeutics to Neutral, Announces $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
Exane BNP Paribas analyst Navann Ty has upgraded Revance Therapeutics from Underperform to Neutral and set a price target of $20.

August 16, 2023 | 11:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance Therapeutics has been upgraded from Underperform to Neutral by Exane BNP Paribas, with a new price target of $20.
The upgrade from Underperform to Neutral by a reputable analyst indicates a more positive outlook for Revance Therapeutics. The new price target of $20 also suggests potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100